Blog Exposure – Exelixis Announces Phase-3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma

Stock Monitor: Syros Pharma Post Earnings
Reporting

LONDON, UK / ACCESSWIRE / November 27, 2017 / Active-Investors issued a free report on Exelixis,
Inc. (NASDAQ: EXEL), which is
readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=EXEL as the Company’s latest news hit the wire. On November
21, 2017, the Company announced that the Phase-3 CELESTIAL trial results have been accepted as a
late-breaking presentation at the 2018 American Society of Clinical Oncology’s
Gastrointestinal Cancers Symposium (ASCO-GI), which will be held January 18–20,
2018, in San Francisco. Sign up now for
our free research reports at: www.active-investors.com/registration-sg.

Active-Investors.com is currently working on the research
report for Syros Pharmaceuticals, Inc. (NASDAQ: SYRS), which also belongs to
the Healthcare sector as the Company Exelixis. Do not miss out and become a
member today for free to access this upcoming report at: www.active-investors.com/registration-sg/?symbol=SYRS.

Active-Investors.com is focused on
giving you timely information and the inside line on companies that matter to
you. This morning, Exelixis most recent news is
on our radar and we have decided to include it on our blog post. Today’s free
coverage is available at: www.active-investors.com/registration-sg/?symbol=EXEL.

Exelixis to Submit NDA to FDA for
Cabozantinib for Advanced HCC Treatment

The
Company plans to submit a supplemental New Drug Application (sNDA) to the US
Food and Drug Administration (FDA) in the first quarter of 2018 for
cabozantinib as a treatment for patients with advanced Hepatocellular Carcinoma
(HCC). In October 2017, the FDA determined Exelixis’ sNDA for CABOMETYX® for
patients with previously untreated advanced Renal Cell Carcinoma (RCC) to be
sufficiently complete to permit a substantive review.

Exelixis’ Phase-3 CELESTIAL Trial of
Cabozantinib Met Primary Endpoint of Overall Survival in Patients with Advanced
HCC

On
October 16, 2017, the Company’s global Phase-3 CELESTIAL trial met its primary
endpoint of overall survival (OS), with cabozantinib providing a statistically
significant and clinically meaningful improvement in median OS compared to
placebo in patients with advanced HCC. The independent data monitoring
committee for the study recommended that the trial should be stopped for
efficacy following review of the second planned interim analysis.

About Hepatocellular Carcinoma (HCC)

HCC
is a primary malignancy of the liver and occurs predominantly in patients with
underlying chronic liver disease and cirrhosis. HCC is the most common type of
primary liver cancer in adults. As with any cancer, the treatment and prognosis
of HCC vary depending on the specifics of tumor histology, size, how far the
cancer has spread, and overall health.

About CELESTIAL

CELESTIAL
is a randomized, double-blind, placebo-controlled study of cabozantinib versus
placebo in patients with advanced HCC. The trial was designed to enroll 760
patients with advanced HCC who received prior sorafenib and may have received
up to two prior systemic cancer therapies for HCC and had adequate liver
function. Patients were randomized 2:1 to receive 60mg of cabozantinib once
daily, or placebo, and were stratified based on etiology of the disease,
geographic region, and presence of extrahepatic spread and/or macrovascular
invasion.

About CABOMETYX® (Cabozantinib)

CABOMETYX
is a prescription medicine used in the United States to treat people with
advanced kidney cancer (renal cell carcinoma) whose cancer has spread, or grown,
after treatment with other cancer medications. Side effects of CABOMETYX includes
coughing up blood or blood clots, red or black stools, menstrual bleeding that
is heavier than normal, or any unusual or heavy bleeding.

In
March 2017, the FDA granted an orphan drug designation to cabozantinib for the
treatment of HCC.

About Exelixis, Inc.

Founded
in 1994, Exelixis is a commercially successful, oncology-focused biotechnology
Company that strives to accelerate the discovery, development, and
commercialization of new medicines for difficult-to-treat cancers. The Company
is headquartered in San Francisco, California.

Stock Performance Snapshot

November
24, 2017 – At Friday’s closing bell, Exelixis’ stock was down 1.07%,
ending the trading session at $25.85.

Volume traded for the
day: 879.28 thousand shares.

Stock performance in the six-month
– up 33.59%; past twelve-month period – up 56.76%; and year-to-date – up 73.37%

After last Friday’s
close, Exelixis’ market cap was at $7.73 billion.

Price to Earnings (P/E)
ratio was at 52.43.

The stock is part of the Healthcare
sector, categorized under the Biotechnology industry. This sector was up 0.3%
at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular
sponsored and non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ and Canadian
stocks. A-I has two distinct and independent departments. One department produces
non-sponsored analyst certified content generally in the form of press
releases, articles and reports covering equities listed on NYSE and NASDAQ and
the other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and micro-caps. Such
sponsored content is outside the scope of procedures detailed below.

A-I
has not been compensated; directly or indirectly; for producing or publishing
this document.

PRESS
RELEASE PROCEDURES:

The
non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service
company (the “Reviewer”) represented by a credentialed financial analyst [for
further information on analyst credentials, please email info@active-investors.com.
Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary
guidance in preparing the document templates. The Reviewer has reviewed and
revised the content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written and reviewed
on a reasonable-effort basis. The Reviewer has not performed any independent
investigations or forensic audits to validate the information herein. The
Reviewer has only independently reviewed the information provided by the Author
according to the procedures outlined by A-I. A-I is not entitled to veto or
interfere in the application of such procedures by the third-party research
service company to the articles, documents or reports, as the case may be.
Unless otherwise noted, any content outside of this document has no association
with the Author or the Reviewer in any way.

NO
WARRANTY

A-I,
the Author, and the Reviewer are not responsible for any error which may be
occasioned at the time of printing of this document or any error, mistake or
shortcoming. No liability is accepted whatsoever for any direct, indirect or
consequential loss arising from the use of this document. A-I, the Author, and
the Reviewer expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on the
information in this document. Additionally, A-I, the Author, and the Reviewer
do not (1) guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.

NOT
AN OFFERING

This
document is not intended as an offering, recommendation, or a solicitation of
an offer to buy or sell the securities mentioned or discussed, and is to be
used for informational purposes only. Please read all associated disclosures
and disclaimers in full before investing. Neither A-I nor any party affiliated
with us is a registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any
questions, inquiries, or comments reach out to us directly. If
you’re a company we are covering and wish to no longer feature on our coverage
list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from
Monday to Friday at:

Email: info@active-investors.com

Phone
number: 73 29 92 6381

Office
Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah
Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by
CFA Institute.

SOURCE: Active-Investors

ReleaseID: 482838